SOPHIA ANTIPOLIS, France—Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported net revenue of  €1.0 million for fourth quarter 2022, ended Dec. 31, 2022, versus net revenue for the fourth quarter of 2021 of €3.5 million. Net revenue for full year 2022 was €3.3 million compared to net revenue for 2021 of €7.2 million. As of Dec. 31, 2022, the Nicox Group had cash and cash equivalents of €27.7 million compared with €42.0 million as of December 31, 2021 and €25.6 million as of September 30, 2022.

The company completed an equity financing in November 2022 and estimates it is now financed until Q2 2024, based exclusively on the development of a glaucoma drug, NCX 470.

As of Dec. 31, 2022, the Nicox Group had financial debt of €20.5 million consisting of €18.7 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and a €1.8 million credit agreement guaranteed by the French State in August 2020 in the context of the COVID-19 pandemic. 

Only the figure related to the cash position of the Nicox Group as of Dec. 31, 2021 is audited; all other figures are non-audited, the company said.